What are the main financial results reported in this 8-K?

This 8-K filing primarily serves to announce Eli Lilly's second-quarter and six-month financial results for 2012. The detailed results are provided in a press release (Exhibit 99) which includes income statements for these periods. The company also shared its financial expectations for the full year 2012.

Why is Eli Lilly using non-GAAP financial measures?

Eli Lilly uses non-GAAP financial measures to provide investors with a clearer view of its ongoing operational performance. These measures exclude certain items that are typically variable, difficult to predict, or of a size that could significantly impact reported results, such as special charges, R&D investments, and restructuring costs. The company believes these adjusted figures help in making meaningful comparisons between different periods and identifying underlying business trends.

What specific items are excluded in the non-GAAP reporting?

The non-GAAP adjustments in this filing typically exclude a special charge related to the withdrawal of Xigris, in-process research and development charges associated with the diabetes collaboration with Boehringer Ingelheim, and restructuring charges related to severance costs from strategic actions to reduce costs and workforce.

Where can I find the detailed financial information and non-GAAP calculations?

The detailed financial results for the second quarter and six months ended June 30, 2012, along with the full year 2012 financial expectations and the specific adjustments made for non-GAAP calculations, are provided in the press release dated July 25, 2012, which is attached as Exhibit 99 to this Form 8-K.

LLY 8-K: Earnings & Results

Summary

Eli Lilly and Company (LLY) filed an 8-K on July 25, 2012, to report its second-quarter and year-to-date financial results for 2012. The filing primarily directs investors to an accompanying press release (Exhibit 99) which details these results and provides forward-looking financial expectations for the full year 2012. A key aspect of the release is its use of non-GAAP financial measures, which exclude certain items like special charges, research and development expenses, and restructuring costs to offer a clearer view of ongoing operational performance. Investors are encouraged to review these non-GAAP measures alongside the standard GAAP financials, as Lilly uses them internally for performance evaluation and resource allocation. The company emphasizes that these adjusted figures aim to provide more meaningful period-over-period comparisons and highlight underlying business trends that might otherwise be obscured by one-time or variable expenses. The press release also includes the company's earnings per share growth expectations for 2012 on a non-GAAP basis.

Key Highlights

1Eli Lilly announced its second-quarter and six-month financial results for 2012 via a press release filed with the 8-K.
2The company provided financial expectations for the full year 2012, including earnings per share growth on a non-GAAP basis.
3The filing prominently features the use of non-GAAP financial measures (e.g., non-GAAP net income, EPS) to present results and guidance.
4Adjustments to GAAP figures include special charges related to Xigris withdrawal, in-process R&D for diabetes collaboration, and restructuring charges from strategic actions.
5Lilly utilizes these non-GAAP measures to offer insights into ongoing operations and facilitate meaningful period-over-period comparisons.
6Management uses non-GAAP measures for internal business evaluation, resource allocation, and incentive compensation assessments.
7The press release and related financial statements are attached as Exhibit 99 to the 8-K filing.

ELI LILLY & Co 8-K Report, Financial Results (Jul 25, 2012)

Summary

Key Highlights

Frequently Asked Questions